Massive Bio Recognized as a Top Cancer Startup
Massive Bio Recognized as a Top Cancer Startup! The list of cancer startups includes those developing new cancer treatments and diagnostics technologies, like genome analysis, patient big data analyses, AI, immunotherapy, antibody therapy, gene therapy, stem cells and more.
Massive Bio was recently selected as a top cancer startup by MedicalStartups.org. Moderna Therapeutics, whose mission is to use mRNA science to create new medicines for patients was also listed. Massive Bio was recognized for bringing cancer genomics to the masses, with a goal of improving quality of care and minimizing costs for cancer patients.
See the full list of top cancer startups here.
What is Genomic Testing?
Cancer, whose incidence increases throughout our age, is defined as uncontrolled division of cells. This uncontrolled proliferation in cells is caused by permanent mutations in genes that control cell division, growth, and survival.
Genomic testing is done to detect changes in the DNA of cancer patients and their tumors, using specialized techniques such as next generation sequencing. In addition, with the help of genomic tests, better targeted cancer treatment can be planned, including personalized treatments.
With the help of genomic tests, better targeted cancer treatment can be planned, including personalized treatments. Thanks to genomic tests, changes in the DNA of cancer patients and tumors can be understood using special techniques such as next generation sequencing.
Why Massive Bio?
Massive Bio’s mission is to create a world without cancer by providing patients with equal access to leading edge therapies and new-emerging clinical trials, regardless of where they live or their ability to pay. Massive Bio continues to work passionately towards this mission and vision to become the hub to connect patients to the best treatments available, including clinical trials.
Massive Bio helps bringing cancer patients first-class healthcare, including clinical trials. Regardless of your geographical location or past medical history, you can participate in a clinical trial that has been reviewed and decided by experts, tailored to your specific cancer type, biomarkers, and needs.
We use our SYNERGY Artificial Intelligence (AI) platform to help you match the most appropriate clinical research based on your cancer type and the current stage of the disease. With more than 170 special clinical algorithms on the platform, Massive Bio fills the gap between patients with clinical research, to help you find novel treatments in real time.